Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because here we are — once again — resuming the usual routine of online calls and deadlines. But as we have pointed out before, the world keeps spinning. So rather than push back, we prefer to give it a nudge in the right direction with a delicious cup of stimulation. Given that this is the start of the week, our choice today is Jack Daniel’s (yes, this is a real thing). So feel free to join us. Meanwhile, here is the latest collection of tidbits we have assembled for the start of your journey. We hope all goes well and that you conquer the world. And of course, do keep in touch. …

So here is the big question for Hal Barron as he departs GlaxoSmithKline (GSK): Did he accomplish his mission, STAT asks. The mission, put simply, was to turn around GSK labs when he was hired as chief scientific officer four years ago. At the time, the drug maker was struggling to develop new medicines, its pipeline not exactly flush. Now, Barron is leaving, having announced he is taking a job as chief executive officer of a new company called Altos Labs, backed with a stunning $3 billion in investor commitments and focused on “cellular rejuvenation programming.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment